

1  
2 **A baseline transcriptional signature associates with clinical malaria risk in RTS,S/AS01-**  
3 **vaccinated African children**

4  
5  
6 **Gemma Moncunill<sup>1\*</sup>, Jason Carnes<sup>2‡+</sup>, William Chad Young<sup>3+</sup>, Lindsay N. Carpp<sup>3+</sup>, Stephen De**  
7 **Rosa<sup>3</sup>, Joseph J. Campo<sup>1,4</sup>, Augusto J. Nhabomba<sup>5</sup>, Maximillian Mpina<sup>6</sup>, Chenjerai Jairoce<sup>5</sup>,**  
8 **Greg Finak<sup>3¶</sup>, Paige Haas<sup>2‡</sup>, Carl Murie<sup>3</sup>, Phu Van<sup>3</sup>, Héctor Sanz<sup>1</sup>, Sheetij Dutta<sup>7</sup>, Benjamin**  
9 **Mordmüller<sup>8€</sup>, Selidji T. Agnandji<sup>8</sup>, Núria Díez-Padrisa<sup>1</sup>, Nana A. Williams<sup>1</sup>, John J. Aponte<sup>1</sup>,**  
10 **Clarissa Valim<sup>9</sup>, Daniel E. Neafsey<sup>10,11‡</sup>, Claudia Daubenberger<sup>12,13‡</sup>, Juliana McElrath<sup>3†</sup>, Carlota**  
11 **Dobaño<sup>1†</sup>, Ken Stuart<sup>2‡†</sup>, Raphael Gottardo<sup>3\*†</sup>**

12  
13  
14  
15 <sup>1</sup> ISGlobal, Hospital Clínic - Universitat de Barcelona, Rosselló 153, Barcelona, Catalonia, Spain.

16 <sup>2</sup> Center for Infectious Disease Research, Seattle, WA, USA.

17 <sup>3</sup> Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA,  
18 USA.

19 <sup>4</sup> Antigen Discovery Inc, Irvine, CA, USA.

20 <sup>5</sup> Centro de Investigação em Saúde de Manhiça (CISM), Rua 12, Cambeve, Vila de Manhiça, Maputo,  
21 Mozambique.

22 <sup>6</sup> Ifakara Health Institute. Bagamoyo Research and Training Centre. P.O. Box 74 Bagamoyo, Tanzania.

23 <sup>7</sup> Walter Reed Army Institute of Research (WRAIR), Silver Spring, MD, USA.

24 <sup>8</sup> Institute of Tropical Medicine and German Center for Infection Research, University of Tübingen,  
25 Tübingen, Germany

26 <sup>9</sup> Department of Global Health, Boston University School of Public Health, Boston, MA, USA.

27 <sup>10</sup> Broad Institute of Massachusetts Institute of Technology and Harvard, Boston, MA, USA.

28 <sup>11</sup> Harvard T.H. Chan School of Public Health, Boston, MA, USA.

29 <sup>12</sup> Swiss Tropical and Public Health Institute, Basel, Switzerland.

30 <sup>13</sup> University of Basel, Basel, Switzerland.

31

32 ‡ These authors contributed equally to this work.

33 + These authors contributed equally to this work.

34 † These authors contributed equally to this work.

35

36 ‡ Current affiliation: Center for Global Infectious Disease Research, Seattle Children's Research  
37 Institute, Seattle, WA, USA.

38 ¶ Current affiliation: Ozette Technologies, Seattle, WA, USA.

39 ¥ Current affiliation: Department of Cellular and Molecular Pharmacology, University of California  
40 San Francisco, San Francisco, CA, USA.

41 € Current affiliation: Department of Medical Microbiology, Radboudumc, Nijmegen, Netherlands.

42

43 \*To whom correspondence should be addressed: [gemma.moncunill@isglobal.org](mailto:gemma.moncunill@isglobal.org) and

44 [rgottard@fredhutch.org](mailto:rgottard@fredhutch.org)

45

46

## 47 **Abstract**

48 In a phase 3 trial in African infants/children, the RTS,S/AS01 (GSK) vaccine showed moderate  
49 efficacy against clinical malaria. We aimed to identify RTS,S/AS01-induced signatures associated with  
50 clinical malaria by analyzing antigen-stimulated peripheral blood mononuclear cells sampled from a  
51 subset of trial participants at baseline and month 3 (one month post-third dose). RTS,S/AS01  
52 vaccination was associated with downregulation of B-cell and monocyte-related blood transcriptional  
53 modules (BTMs) and upregulation of T-cell related BTMs, as well as higher month 3 (vs baseline)  
54 circumsporozoite protein (CSP)-specific CD4<sup>+</sup> T-cell responses. There were few RTS,S/AS01-  
55 associated BTMs whose month 3 levels correlated with malaria risk. In contrast, baseline levels of  
56 BTMs associated with dendritic cells and with monocytes (among others) correlated with malaria risk.  
57 A cross-study analysis supported generalizability of the baseline dendritic cell- and monocyte-related  
58 BTM correlations with malaria risk to healthy, malaria-naïve adults, suggesting inflammatory  
59 monocytes may inhibit protective RTS,S/AS01-induced responses.

60

## 61 **Introduction**

62 Malaria remains a serious public health problem, with an estimated 229 million cases and 409,000  
63 related deaths in 2019 (1). Despite the strides that interventions such as long-lasting insecticide treated  
64 bed nets, improved vector control and diagnostic tests, and mass antimalarial drug administration  
65 campaigns have made towards reducing malaria-related morbidity and mortality (2, 3), there is a  
66 critical need for an effective malaria vaccine (4, 5).

67 The RTS,S/AS01 malaria vaccine targets the pre-erythrocytic stage of the parasite life cycle and has  
68 been designed to elicit strong humoral and cellular immune responses against the *Plasmodium*  
69 *falciparum* circumsporozoite protein (CSP) (6). This recombinant vaccine consists of a protein

70 containing multiple immunodominant NANP repeats and the carboxy terminus of CSP fused to  
71 hepatitis B virus surface antigen (HBs) formulated in the AS01 adjuvant (7).

72 In a phase 3 trial in 15,459 African infants and children (ClinicalTrials.gov NCT00866619) (8-11),  
73 RTS,S/AS01 demonstrated 56% vaccine efficacy (VE) against clinical malaria (follow up time: 12  
74 months post-last dose) in children aged 5-17 months at enrollment and 31% in infants aged 6-12 weeks  
75 at enrollment. In 2015, RTS,S/A01 became the first malaria vaccine to receive a positive opinion by the  
76 European Medicines Agency under Article 58 (12), and it was recommended by the World Health  
77 Organization for a malaria vaccine pilot implementation program in Ghana, Malawi, and Kenya that  
78 started in 2019 (13).

79 A critical limitation of the RTS,S vaccine is that VE is moderate (lower in infants than children) and  
80 wanes substantially within the first 18 months (10). The identification of immune correlates of  
81 protection could help guide iterative vaccine improvements and expedite vaccine evaluation. Excellent  
82 work has been done on elucidating correlates of RTS,S/AS01-mediated protection in healthy, malaria-  
83 naïve adults using the controlled human malaria infection (CHMI) model (14-20), and cohort studies in  
84 African infants and children have implicated vaccine-induced anti-CSP antibodies (21-23), as well as  
85 CSP-specific Th1 cytokines (24), and CD4<sup>+</sup> T cells (albeit to a lesser extent) in protection in this  
86 population (reviewed in (25)).

87 The MAL067 study, an ancillary study to the RTS,S/AS01 phase 3 trial, was conducted to address key  
88 knowledge gaps of RTS,S induced immune responses and their correlation with protection against field  
89 challenge. Using RNA-sequencing (RNA-seq) data from antigen- or vehicle-stimulated PBMC  
90 obtained at baseline and one month post-final dose from infants and children enrolled in Bagamoyo,  
91 Tanzania and Manhica, Mozambique, we aimed to identify baseline and/or RTS,S/AS01-induced  
92 signatures associated with clinical malaria risk. Post-vaccination anti-CSP antibody titers, cytokine  
93 profiles, and T-cell responses, the latter of which were additionally assessed in samples from

94 participants enrolled in Lambaréné, Gabon, were also examined as correlates of clinical malaria and/or  
95 of RTS,S/AS01-induced transcriptional responses.

96 The major finding of our study is that pre-vaccination expression of immune-related blood  
97 transcriptional modules (BTMs), including BTMs related to dendritic cells and monocytes, correlated  
98 positively with malaria risk in RTS,S/AS01-vaccinated African children; moreover, this dendritic cell-  
99 and monocyte-related signature appeared to be generalizable to malaria-naïve RTS,S/AS01-vaccinated  
100 healthy adults.

101


## 102 **Materials and Methods**

### 103 *MAL067 trial*

104 During the MAL055 Phase 3 study (ClinicalTrials.gov identifier NCT00866619; (11)), infants (6-12  
105 weeks) and children (5-17 months) received RTS,S/AS01 or comparator (rabies vaccine for children;  
106 meningococcal C conjugate vaccine for infants), with injections given at month 0 (baseline), month 1,  
107 and month 2 (Figure 1). MAL067 was a multi-center immunology ancillary study nested within  
108 MAL055 and selection of participants for MAL067 is described in (24). Of the seven trial sites  
109 included in MAL067, PBMC samples were collected at baseline (only children) and again at month 3  
110 (one-month post-third dose) at three. The present study analyzes PBMC data from children in  
111 Bagamoyo (Tanzania) and from infants and children in Manhiça (Mozambique), as well as from infants  
112 and children in Lambaréné (Gabon) (only intracellular cytokine staining (ICS)/immunophenotyping for  
113 the latter). All malaria cases with samples collected were included together with 2 to 3 matched non-  
114 malaria controls for each malaria case, prioritizing subjects who had samples at both month 0 and  
115 month 3 and in whom the complete set of antigen stimulations was conducted.

116

117



118

119

120 **Figure 1: Schematic showing vaccination and sampling schedule.** Participants received

121 RTS,S/AS01 (or comparator) at month 0, month 1, month 2; peripheral blood mononuclear cells

122 (PBMC) were collected for RNA-sequencing at month 0 and month 3 (1 month post-final dose). Stim,

123 stimulation.

124

125

126 *Case-control definitions*

127 Cases were defined as participants who had any episode of clinical malaria (fever  $>37.5^{\circ}\text{C}$  with any

128 parasitemia by blood smear) in the 12 months of follow up after month 3.5, identified by passive case

129 detection (subjects who sought care at a health facility). Controls were participants who did not have

130 any clinical malaria case during the 12 months of follow-up. Controls were matched to cases based on

131 site, age group, and time of vaccination and follow-up. Up to 3 controls were selected for each case

132 among RTS,S/AS01 vaccinees, and 2 controls were selected for each case among comparator  
133 vaccinees.

134

#### 135 *PBMC collection and antigen stimulation*

136 PBMC collection and stimulation with DMSO (vehicle control), apical membrane antigen  
137 (recombinant AMA1, FVO strain), CSP (peptide pools), or HBS (peptide pools) is described in (24).  
138 For stimulation before RNA extraction,  $4 \times 10^5$  freshly isolated PBMC seeded in duplicates were rested  
139 for 12 h and then incubated 12 h at 37°C with 1 µg/mL antigens in 96 well-plates. Plates were then  
140 centrifuged for 5 min at 250g at room temperature and cell pellet duplicates were resuspended and  
141 pooled in RL Tbuffer at Bagamoyo or RNAprotect (Qiagen) at Manhiça, transferred into a 96 well V-  
142 bottomed plate (Kisker, AttendBio G096-VB) and sealed with adhesive foil (Kisker, Attend Bio G071-  
143 P) and cryopreserved at -80°C till RNA extraction.

144 For stimulation before ICS, cryopreserved PBMC were thawed and then rested in a 37°C, 5% CO<sub>2</sub>  
145 incubator overnight. PBMC were stimulated for 6 h with the same peptide pools as above, DMSO  
146 (vehicle control), and Staphylococcal enterotoxin B as a positive control.

147

#### 148 *Flow immunophenotyping*

149 Leftover cryopreserved PBMC thawed for ICS ( $0.5-1 \times 10^6$  cells) were used for leukocyte phenotyping.  
150 The flow cytometry panel and staining protocol used is described in (26). Data were acquired using a  
151 BD LSR II flow cytometer (BD Biosciences) directly from 96-well plates using a high throughput  
152 sampler. Flow cytometry analysis was performed using FlowJo software (Version 9.9 Tree Star). The  
153 gating strategy was performed as in (26, 27).

154

#### 155 *Intracellular cytokine staining*

156 Antigen-or vehicle-stimulated PBMC were stained using a flow cytometry panel and protocol  
157 previously described (27, 28) with the additional marker IL-13. Antibody details can be found in Table  
158 S1. Data was acquired and analyzed as above.

159

#### 160 *RNA isolation and sequencing*

161 RNA was extracted at the Center for Infectious Disease Research (CIDR, Seattle) using the Promega  
162 SV 96 RNA Isolation kit following the manufacturer's protocol. Samples kept in RNAProtect were  
163 centrifuged at 4,000g for 7 minutes at 4°C, cell pellets were resuspended in 150 µL RLT Buffer, and  
164 150 µL of 70% ethanol was added prior to processing with Promega SV 96 RNA Isolation kit. RNAs  
165 were eluted with 100 µL nuclease free water. Each 96-well extraction batch was spot checked by  
166 Bioanalyzer using Agilent RNA 6000 Pico chip and had an average RIN score of 7.4. RNA samples  
167 were distributed in 384 well plates for library preparation. Samples from the same individuals were in  
168 the same plate and key study variables (vaccine, site and cases-controls) were checked for balance  
169 across plates to avoid batch effects.

170 An optimized version of Digital Gene Expression (DGE) was used, further reducing the reverse  
171 transcriptase reaction volume. In brief, poly(A)+ mRNA from antigen-stimulated PBMCs was linked to  
172 unique molecular identifiers (UMIs) using a template-switching reverse transcriptase. Then, cDNA  
173 from multiple cells were pooled, amplified, and prepped for multiplexed sequencing using a  
174 transposon-based fragmentation method, enriching for 3' ends and preserving strand information.  
175 Nextera XT library preparation and sequence paired-ends were employed on an Illumina NextSeq  
176 instrument at the Broad Institute.

177

#### 178 *Immunogenicity data analyzed for correlations with BTM expression*

#### 179 **Antibody**



180 NANP-specific, HBS-specific, and C terminal domain of CSP (C-term)-specific antibody data from  
181 previous studies were analyzed for correlations with BTM expression as described below. IgG titers  
182 (EU/mL) against NANP and against HBS were obtained from the MAL055 trial database (8-11). IgG  
183 titers (EU/mL) against NANP and C-term were measured by ELISA at IAVI-HIL (21). IgG and IgM  
184 levels (Median Fluorescence Intensity, MFI) against NANP, C-terminal CSP and HBS together with 35  
185 RTS,S/AS01 vaccine-unrelated malaria antigens were measured by Luminex technology (22, 23).

186

### 187 **Cellular**

188 Data from cytokines in the supernatants of the same CSP and HBS PBMC stimulations analyzed by  
189 Luminex in a previous study (24) were used here for detecting BTMs correlated with RTS,S/AS01  
190 immunogenic responses.

191

### 192 *Data processing and statistical analysis*

193 Preprocessing: Preprocessing of RNAseq data was done by Broad Technology Labs. In brief, reads  
194 were aligned using BWA Aln version 0.7.10 using UCSC RefSeq (Human 19) with mitochondrial  
195 genes added. Quantified samples were then quality controlled using mapping summary statistics to  
196 remove low quality samples based on predetermined minimum values for the total number of mapped  
197 reads, percent of mapped reads mapped to the human genome, etc. Downstream analysis was applied  
198 only to reads that mapped uniquely to a UMI and only mapped to isoforms of the same gene  
199 (UMI.unq).

200

201 Normalization: The TMM normalization method (29) was applied to account for differing number of  
202 read counts and to address unwanted technical variation. The voom transformation (30) from the limma  
203 R package (31) was applied to standardize and appropriately weight the data for use in linear models.

204

205 Quality control: In a pilot study, we found that sample libraries that exhibit less than 75,000 total  
206 RNAseq reads per sample were of low quality. Thus, such libraries were removed from the study.  
207 Genes that had less than 20 samples (around 10%) with read counts greater than 5 were also removed.  
208 For further details, see the Supplementary Methods.  
209  
210 Differential expression: Differential expression was assessed using module-based (using voom and  
211 camera (32)) approaches as implemented in the limma package. Camera, combined with voom, is one  
212 of the few gene set enrichment analysis methods that can properly account for inter-gene correlation in  
213 RNA-seq data. Specifically, Camera estimates the variance inflation factor for the gene expression that  
214 results from inter-gene correlation in the data and incorporates it into test procedures to control the  
215 apparent false discovery rate. This step is important since significant correlation is expected among  
216 genes in the same module. Inference was based on p-values adjusted for multiple testing by controlling  
217 the false discovery rate with the Benjamini-Hochberg (33) method. Differential expression was used to  
218 down-select modules constituting the PBMC transcriptional response to RTS,S/AS01 vaccination  
219 comparing RTS,S/AS01 vaccinees with comparator at month 3 and pre- and post-RTS,S/AS01E  
220 vaccination in children (month 3 vs month 0). Noninformative modules (“TBA”) are omitted from all  
221 heatmaps.  
222  
223 Blood transcriptional module (BTM) analysis: BTMs used were from Li et al. (34). Resulting p-values  
224 across BTMs (within stimulation condition) were adjusted for multiple testing with a false discovery  
225 rate (FDR) cutoff of 0.2. Only these significant BTMs were tested as candidate immune correlates.  
226  
227 BTM correlations with immunogenicity:  
228 For each module, a score was calculated for each RTS,S recipient at month 3 and at month 0 based on  
229 the average normalized expression level of all genes in the modules, on the log scale. Spearman’s rank

230 correlation was used to assess association between gene expression, functional antibody and cellular  
231 responses. Each correlation was tested (Pearson correlation test) and a p-value was obtained. P-values  
232 were adjusted within each response (across all gene sets); significance was defined as an adjusted p-  
233 value  $\leq 0.2$ .

234

235 Correlates analysis: We identified BTMs significantly associated with protection using the limma  
236 package. The model adjusted for clinical and experimental covariates such as age and technical  
237 experimental factors. This model was applied to each BTM and stimulation condition identified in the  
238 down-selection process. Resulting p-values were adjusted for multiple testing with an FDR cutoff of  
239 0.2.

240

241 For the cross-study correlates analysis, BTMs were down-selected based on month 3 or month 0 (as  
242 appropriate) data from MAL067 (vehicle-stimulated PBMC only). In brief, month 3 or month 0 data  
243 for every BTM were tested and FDR adjustment was done across all BTMs. Only those BTMs with  
244  $FDR < 0.2$  in MAL067 were examined as potential correlates of challenge outcome in the CHMI  
245 studies, with FDR adjustment performed within each study.

246

247 Logistic regression: Conditional logistic regression was applied to assess which monocyte populations  
248 were predictive of clinical malaria. The clogit function from the R survival package was used and  
249 incorporated a stratified variable which grouped subjects according to a set of personal and clinical  
250 factors.

251

252 Analysis of antigen (Ag)-specific T cells: When analyzing Ag-specific T cells, vehicle-only  
253 stimulations (DMSO) were used to determine the effect of Ag stimulation over vehicle stimulation for  
254 each PBMC sample. The comparison was performed using the limma package (35) in R as follows:

255 stimulation\*vaccine, where stimulation = (HBS, AMA1, CSP) vs vehicle and vaccine = RTS,S/AS01  
256 vs Comparator.

257

258

## 259 **Results**

### 260 *Study population and sample collection scheme*

261 PBMC RNA-seq data from a total of 193 participants were analyzed (Table 1). Baseline RNA-seq data  
262 were available for 36 recipients (8 cases, 28 controls) and 19 comparator recipients (5 cases, 14  
263 controls), all of whom were children since baseline samples were not collected from infants. Month 3  
264 RNA-seq data were available for 123 RTS,S/AS01 recipients (30 cases, 93 controls) and 70 comparator  
265 recipients (23 cases, 47 controls). All (100%) of the participants in Bagamoyo for whom Month 3  
266 RNA-seq data were available were children, whereas nearly all (94.9%) in Manhiça were infants.  
267 Table S2 provides similar information for participants for whom immunophenotyping/ICS data were  
268 analyzed.

269

270 **Table 1: Numbers, age group, and case-control status of participants by site for whom PBMC**  
271 **RNA-seq data were available at month 0 and/or at month 3.**

272

Month 0					
Total Participants (Total Participants at Bagomoyo, Total Participants at Manhiça)					
	Cases			Controls	
	Total	Infants	Children	Infants	Children
RTS,S/AS01	36 (36, 0)	0 (0, 0)	8 (8, 0)	0 (0, 0)	28 (28, 0)
Comparator	19 (17, 2)	0 (0, 0)	5 (5, 0)	0 (0, 0)	14 (12, 2)

<b>Month 3</b>					
<b>Total Participants (Total Participants at Bagomoyo, Total Participants at Manhiça)</b>					
	Cases			Controls	
	Total	Infants	Children	Infants	Children
RTS,S/AS01	123 (70, 53)	12 (0, 12)	18 (18, 0)	41 (0, 41)	52 (52, 0)
Comparator	70 (45, 25)	6 (0, 6)	17 (16, 1)	15 (0, 15)	32 (29, 3)

273

274

275

276 *RTS,S/AS01* vaccination is associated with month 3 downregulation of B cell- and monocyte-related

277 BTMs, along with upregulation of T cell-related BTMs

278 The transcriptional response to RTS,S/AS01 vaccination was assessed in control-stimulated PBMC as  
 279 well as Ag-stimulated PBMC. Through this approach, we hypothesized that we would see recall  
 280 responses of Ag-specific T cells activated *in vitro*, as well as responses of other cell types to the  
 281 secreted cytokines/chemokines. Of note, the sampling schedule at MAL067 was designed for  
 282 evaluation of acquired immune responses to the vaccine and not *ex vivo* responses. Our motivation was  
 283 that in healthy, malaria-naïve adults, the transcriptional response to RTS,S/AS01 has been shown to  
 284 largely wane by Week 3 post-final dose (16), implying that the majority of the RTS,S/AS01-induced  
 285 transcriptional changes in this study likely preceded the month 3 sample collection. Three antigens  
 286 were chosen for stimulation: CSP (peptides covering the CSP region of RTS,S that encodes B-cell and  
 287 T-cell epitopes), HBS (peptides covering the HBS, also included in the RTS,S vaccine), and AMA1 (a  
 288 highly immunogenic antigen expressed briefly on hepatocyte-invading *P. falciparum* sporozoites and  
 289 predominantly on red blood cell-invading *P. falciparum* merozoites, not present in the RTS,S vaccine;  
 290 included to analyze naturally acquired immunity responses).


291 Two comparisons were done to characterize the transcriptional response to RTS,S/AS01 vaccination:  
292 Comparison (1): comparing gene expression in month 3 samples from RTS,S/AS01 vs comparator  
293 recipients (month 3 RTS,S/AS01 vs comparator); and Comparison (2): comparing gene expression in  
294 month 3 vs month 0 from RTS,S/AS01 recipients (RTS,S/AS01 month 3 vs month 0). Each  
295 comparison has its own advantages: Comparison (1) allows the identification of RTS,S/AS01-specific  
296 responses while taking into account other environmental factors to which the children are exposed,  
297 such as malaria exposure (albeit malaria transmission intensity was low during the study at both sites).  
298 Moreover, the very young ages of the trial participants mean that RTS,S/AS01-induced changes may be  
299 confounded with normal developmental changes in participant immune systems, further underscoring  
300 the value of Comparison (1), as it does not involve comparison across two different time points. On the  
301 other side, an advantage of Comparison (2) is that it takes into consideration each participant's intrinsic  
302 baseline gene expression. Comparison (1) uses data from both infants and children, whereas  
303 Comparison (2) can only yield insight into RTS,S/AS01 responses in children (as baseline samples  
304 were not collected from infants).

305

306 A BTM-based approach was taken to reduce dimensionality, avoid paying a high penalty for multiple  
307 testing, and aid results interpretability. For Comparison (1), there were 59 significantly differentially  
308 expressed (FDR cutoff  $\leq 0.2$ ) BTMs across all antigen stimulation conditions (Figure 2, Table S3a).  
309 The vast majority (55) of these BTMs were in vehicle-treated PBMCs, with few differences observed  
310 in antigen-stimulated PBMCs (0 significantly differently expressed BTMs in CSP-stimulated PBMC  
311 and 8 significantly differentially expressed BTMs in AMA1-stimulated PBMC). The categories with  
312 the most differentially expressed BTMs were B cells and T cells: In vehicle-stimulated PBMCs from  
313 infants/children who received RTS,S/AS01, 11 T cell-related BTMs were upregulated (vs comparator).  
314 We also observed that natural killer (NK) cell and mitochondria-related BTMs were upregulated in  
315 vehicle-stimulated PBMC, whereas B cell-related BTMs were downregulated. Counter to our initial

316 expectations, no significant correlations were identified in the CSP-stimulated cells. This result may  
 317 potentially be explained by the low frequency of CSP-specific T-cells in RTS,S/AS01 vaccinees (e.g.  
 318 on average, <0.10% of all CD4+ T cells (28)). In AMA1-stimulated cells, surprisingly, the few  
 319 correlate BTMs that were identified tended to correlate in opposite directions with risk than in the  
 320 vehicle-stimulated PBMC (i.e. a positive correlate in vehicle-stimulated PBMC yet an inverse correlate  
 321 in AMA1-stimulated PBMC, and vice versa). We hypothesize that cytokines/chemokines released from  
 322 activated T cells and their effects on other PBMC may underlie this difference. Alternatively, AMA1  
 323 may be eliciting an innate response, which is supported by the findings of Bueno et al. in the context of  
 324 *P. vivax* (36).

325



326

327 **Figure 2: Transcriptional responses and antigen-specific transcriptional responses at one month**  
328 **post-final dose associated with RTS,S/AS01 vaccination. A)** Comparison 1: month 3 (M3) PBMC,  
329 RTS,S/AS01 vs comparator; **B)** Comparison 2: M3 PBMC vs. month 0 (M0) PBMC, RTS,S/AS01  
330 recipients only. Cell color intensity represents the strength of the difference in the relevant comparison,  
331 expressed as signed  $\log_{10}$  false discovery rate (FDR); blood transcriptional modules (BTMs) with  
332 significantly different expression (false discovery rate  $\leq 0.2$ ) between the two compared groups are  
333 outlined in black. Red, higher expression in RTS,S/AS01 recipients vs comparator recipients at M3  
334 (Comparison 1) or higher expression in RTS,S/AS01 recipients at M3 vs M0 (Comparison 2); blue,  
335 lower expression in RTS,S/AS01 recipients vs comparator recipients at M3 (Comparison 1) or lower  
336 expression in RTS,S/AS01 recipients at M3 vs M0 (Comparison 2). High-level BTM annotation  
337 groups are shown in the left-most color bar.

338

339 For Comparison (2), only RTS,S/AS01 recipients for whom month 0 and month 3 samples were  
340 available were included in the analysis (i.e., children only). There were 67 significantly differentially  
341 expressed (FDR cutoff  $\leq 0.2$ ) BTMs, all in vehicle-stimulated PBMC (Figure 2, Table S3b).

342 Antiviral/interferon (IFN)-, inflammatory/Toll-like receptor (TLR)/chemokine-, dendritic cell-, and  
343 transcription-related BTMs were among those upregulated, whereas B cell- and monocyte-related  
344 BTMs were among those downregulated.

345 The two Comparisons yielded partially divergent results, likely due to the reasons stated above.

346 However, downregulation of monocyte-related BTMs in vehicle-treated PBMC was consistently  
347 observed across the two Comparisons: “Enriched in monocytes (II) (M11.0)” was downregulated in  
348 both Comparisons, “Enriched in myeloid cells and monocytes (M81)” was downregulated in  
349 Comparison (1), and “Monocyte surface signature (S4)” and “Enriched in monocytes (surface)  
350 (M118.1)” were downregulated in Comparison (2). Interestingly, monocyte-related BTMs (including



351 these four BTMs) were upregulated at multiple time-points in response to RTS,S/AS01 administration  
352 in (16), pointing to differences between the two study populations.

353

354 *Monocyte-related RTS,S/AS01 signature BTMs associate with clinical malaria risk*


355 To preserve statistical power in the immune correlates analysis, only BTMs differentially expressed  
356 after RTS,S/AS01 vaccination according to Comparison 1 (any stimulation) were down selected. We  
357 define these 59 BTMs as the “RTS,S/AS01 signature BTMs”. We next investigated if any of the  
358 RTS,S/AS01 signature BTMs were associated with clinical malaria risk in RTS,S/AS01 recipients, by  
359 comparing expression of the signature BTMs in cases vs. controls, within each stimulation condition.

360

361 In vehicle-stimulated PBMC, five BTMs were significantly differently expressed in RTS,S/AS01 cases  
362 vs controls (Figure 3, Table S4): “Myeloid cell enriched receptors and transporters (M4.3)” (up),  
363 “Respiratory electron transport chain (mitochondrion) (M219)” (down), “Respiratory electron transport  
364 chain (mitochondrion) (M238)” (down), “Enriched in myeloid cells and monocytes (M81)” (up), and  
365 “Enriched in monocytes (II) (M11.0)” (up). The results suggest a direct correlation of monocyte  
366 activity and an inverse correlation of mitochondrial oxidative phosphorylation 1-month post-primary  
367 vaccination with clinical malaria risk. The association of monocyte-related BTMs with risk is  
368 consistent with studies reporting a positive correlation between monocyte/lymphocyte ratio and clinical  
369 malaria risk and/or severity (37, 38).

370

371



372

373

374 **Figure 3: Associations of month 3 levels of RTS,S/AS01 signature blood transcriptional modules**

375 **(BTMs) with malaria case status in RTS,S/AS01 recipients.** Heatmap showing down-selected

376 signature BTMs (Comparison 1) with significantly different expression [false discovery rate (FDR)  $\leq$

377 0.2] in month 3 PBMC from RTS,S/AS01 malaria cases vs. non-malaria controls, in at least one

378 stimulation condition. Cell color intensity represents the strength of the difference in the relevant

379 comparison, expressed as signed  $\log_{10}$  FDR; BTMs with significantly different expression in the

380 comparison are outlined in black. Red, higher expression in RTS,S/AS01 cases vs. controls; blue, lower

381 expression in RTS,S/AS01 cases vs. controls. High-level BTM annotation groups are shown in the left-

382 most color bar.

383

384 Antigen-stimulated PBMC also showed transcriptional modules associated with clinical malaria risk.

385 However, these results differed largely from those seen in vehicle-stimulated PBMC. The two

386 monocyte-related BTMs (M81, M11.0) that were directly associated with risk in vehicle-stimulated

387 PBMC were inverse correlates in both HBS- and AMA1-stimulated PBMC. Moreover, five T-cell

388 related BTMs were positive correlates of risk in AMA1-stimulated PBMC (Figure 3).

389 The same analysis was performed on comparator recipients (Figure S1). For all five BTMs whose

390 levels in vehicle-stimulated PBMC associated either directly or inversely with risk in RTS,S/AS01

391 recipients (Figure 3), significant correlations were observed in the opposite direction in comparator

392 recipients (Figure S1), suggesting that positive correlations of the three monocyte-related BTMs with

393 risk and inverse correlations of the mitochondria-related BTMs with risk are specific to RTS,S/AS01

394 recipients.

395

### 396 *Polyfunctional CSP-specific CD4<sup>+</sup> T-cell responses*

397 In addition to transcriptional changes, our group has shown previously that RTS,S/AS01 vaccination

398 elicits vaccine-specific antibody and cellular responses in African infants and children (e.g. (21, 23,

399 28)). The polyfunctionality score is a summary measure that encapsulates a participant's entire Ag-

400 specific T-cell response after vaccination (39). Using data from a pilot study of 179 children (none of

401 whom was a malaria case) at the Manhiça and Bagamoyo sites, Moncunill et al. previously showed that

402 MAL067 RTS,S/AS01 recipients have higher month 3 CSP-specific and HBS-specific CD4<sup>+</sup> T-cell

403 polyfunctionality scores than comparator recipients (28). Consistent with this finding, we report that

404 average CSP-specific CD4<sup>+</sup> T-cell polyfunctionality and magnitude (frequency of CD4<sup>+</sup> T-cell


405 expressing IL-2 or TNF or CD154) are both higher at month 3 vs. baseline in RTS,S/AS01 vaccine

406 recipients (Figure 4). The few high responders at baseline can likely be attributed to prior malaria

407 exposure. However, there was no difference in average month 3 CSP-specific T-cell response  
408 polyfunctionality or magnitude between RTS,S/AS01 cases vs controls (Figure S2).

409

410



411

412 **Figure 4: RTS,S/AS01 vaccination elicits polyfunctional T-cell responses.** Boxplots show **A)**

413 polyfunctionality score and **B)** magnitude (% CD4+ T cells expressing IL2 or TNF- $\alpha$  or CD154) of

414 CSP-specific CD4+ T-cell responses in RTS,S/AS01 recipients as assessed by intracellular cytokine

415 staining of PBMC collected at month 0 (M0) or at month 3 (M3). Each dot represents a single

416 participant. Data plotted include all available month 0 and month 3 samples, i.e. paired month 0-month

417 3 samples were not required for plotting. P values represent two-sample test values.

418

419

420 *Month 3 levels of RTS,S/AS01 signature BTMs tend to correlate directly with month 3 IgM antibody*

421 *responses and inversely with month 3 IgG responses*


422 We next investigated whether month 3 levels of the RTS,S/AS01 signature BTMs were associated with

423 month 3 humoral immune responses in RTS,S/AS01 vaccinees. In vehicle-treated PBMC, both positive

424 and negative associations were seen for multiple antibody variables across functional categories (Figure

425 5, Table S5). The three antibody variables whose month 3 levels had the strongest positive correlations  
 426 with transcriptional data were “IgM, LSA1”, “IgM, MSP1 b12 Mad20”, and “IgM, MSP6”, which  
 427 tended to be positively correlated with month 3 levels of DC-, inflammatory/TLR/chemokine-, and  
 428 monocyte-related BTMs. In contrast, month 3 levels of “IgG, AMA1 3D7” and “IgG, AMA1 FVO”  
 429 tended to be inversely correlated with month 3 levels of DC- and monocyte-related BTMs. None of  
 430 these associations were seen in comparator recipients (Figure S3), suggesting specificity to  
 431 RTS,S/AS01 receipt, although we note that sample size is smaller which would have reduced statistical  
 432 power to detect differences. Month 3 levels of cellular variables assessed by polychromatic flow  
 433 cytometry did not correlate significantly with the month 3 level of any BTM.

434



435

436 **Figure 5: Correlations of month 3 transcriptional and adaptive responses in RTS,S/AS01 vaccine**  
437 **recipients.** Heatmap showing correlations between month 3 levels of RTS,S/AS01 signature BTMs  
438 and month 3 antibody and cellular responses. Cell color intensity represents the strength of the  
439 correlation; BTM/response pairs with significant correlations [false discovery rate (FDR)  $\leq 0.2$ ] are  
440 outlined in black. Cell color represents correlation direction: red, positive correlation; blue, negative  
441 correlation. High-level BTM annotation groups are shown in the left-most color bar. The bottom bar  
442 denotes the type of adaptive response analyzed (orange, antibody; purple, cellular). Red font: CSP-  
443 specific IFN- $\gamma$  responses have been associated with protection against parasitemia in controlled human  
444 malaria infection studies (40, 41); corresponding heatmap squares representing significant  
445 BTM/response correlations are bordered in red.

446

447

448 In Ag-stimulated PBMCs, significant correlations of month 3 levels of both antibody and cellular  
449 variables with month 3 BTM levels were also observed (Figure 5, Table S5); as above, the correlations  
450 were widely spread across BTM functional groupings. For HBS- and AMA1-stimulated PBMCs,  
451 antibody variables with the most correlations included “IgM, LSA1” and “IgM, MSP6”. Correlations of  
452 month 3 cellular variables with month 3 BTM levels in CSP-stimulated and in HBS-stimulated PBMC  
453 were generally positive. Of interest were inverse correlations of month 3 levels of “Resting dendritic  
454 cell surface signature (S10)” and “DC surface signature (S5)” with CSP-specific IFN- $\gamma$  responses  
455 (which have been associated with protection in CHMI studies (40, 41) and in the MAL067 study (24)).  
456 In general, much fewer associations were seen for comparator recipients (Figure S3). Specifically, the  
457 inverse associations of CSP-specific IFN- $\gamma$  responses with month 3 levels of DC-related BTMs were  
458 not seen, suggesting that these associations are RTS,S/AS01-specific.

459

460 *Cross-study immune correlates analysis reveals a mostly consistent association in RTS,S/AS01-*  
461 *vaccinees between baseline expression of DC- and monocyte-related BTMs and risk*


462 An important question is whether the results of our analysis of the MAL067 trial, which was conducted  
463 in African infants and children in malaria-endemic areas, are generally translatable to other study  
464 populations. PBMC transcriptomic data are available for at least three different controlled human  
465 malaria infection (CHMI) studies conducted in a quite different study population, i.e. healthy, malaria-  
466 naïve adults in the United States. WRAIR 1032 ([NCT00075049](https://clinicaltrials.gov/ct2/show/study/NCT00075049)) randomly assigned participants to  
467 receive RTS,S/AS02A or RTS,S/AS01B at months 0, 1, and 2 (40); MAL068 (NCT01366534)  
468 randomly assigned participants to receive Ad35.CS.01 at month 0 followed by RTS,S/AS01B at  
469 months 1 and 2 (heterologous prime-boost) or RTS,S/AS01B at months 0, 1, and 2 (14); and MAL071  
470 ([NCT01857869](https://clinicaltrials.gov/ct2/show/study/NCT01857869)) randomly assigned participants to receive a full dose of RTS,S/AS01B at months 0, 1,  
471 and 2 or a full dose of RTS,S/AS01B at months 0 and 1, followed by a fractional dose at month 7 (42).  
472 Importantly, all these trials share a common vaccine arm: one full dose of RTS,S/AS01B at months 0,  
473 1, and 2 (referred to as the “RRR” arm). Microarray data from WRAIR 1032 were analyzed by Vahey  
474 et al. (43), microarray data from MAL068 were analyzed by Kazmin et al. (16), and RNA-seq data  
475 from MAL068 and MAL071 were analyzed by Du et al. (17).

476 We performed a cross-study immune correlates analysis where we examined whether the BTMs  
477 associated with clinical malaria risk in MAL067 showed similar associations with challenge outcome  
478 in each of the three CHMI studies described above. Due to differences in sampling schedules, and the  
479 presence of the CHMI challenge (which would complicate results interpretation), we could not  
480 compare the exact same month 3 timepoint across studies. We chose instead to compare 21 days post-  
481 third dose in MAL068 and in MAL071, i.e. of day of challenge, and 14 days post-third dose in WRAIR  
482 1032, i.e. just before or on day of challenge. We refer to these slightly different post-vaccination time  
483 points as “month 3” for simplicity. The month 3 cross-study correlates analysis included BTMs whose  
484 month 3 levels (in vehicle-stimulated PBMC) associated with clinical malaria risk in MAL067


485 RTS,S/AS01B recipients (Figure 3, Table S4) and is shown in Figure 6A. No BTM was consistently  
486 associated with malaria risk (or non-protection) across all four studies. The most consistent result was  
487 for the monocyte-related BTMs, where month 3 expression of “enriched in monocytes (II) (M11.0)”  
488 was significantly associated with risk in 3 of the 4 studies (all except WRAIR 1032), and “enriched in  
489 myeloid cells and monocytes (M81)” was significantly associated with risk in MAL067 and MAL071  
490 RRR (Figure 6A, Table S6A).  
491



**A** Month 3



**B** Month 0



492

493

494 **Figure 6. Associations of (A) month 3 or (B) month 0 levels of blood transcriptional modules**

495 **(BTMs) with malaria case status in MAL067 RTS,S/AS01 vaccine recipients across studies**

496 **sharing a common month 0, month 1, month 2 RTS,S/AS01 arm. A) Heatmap showing the**

497 difference in month 3 PBMC BTM expression between RTS,S/AS01 malaria cases vs. non-malaria  
498 controls in each of three CHMI studies of the 5 BTMs whose month 3 levels in DMSO-stimulated  
499 PBMC associated with malaria case status in MAL067 (Figure 3). Note that “month 3” = 21 days post-  
500 final dose in MAL068 and MAL071, and 14 days post-final dose in WRAIR 1032; we refer to these  
501 slightly disparate post-vaccination time points as “month 3” for simplicity. BTMs with significantly  
502 different expression [false discovery rate (FDR)  $\leq 0.2$ , with adjustment done across the 5 BTMs] are  
503 outlined in black. **B)** Heatmap showing the 35 BTMs whose month 0 levels showed significantly  
504 different expression in MAL067 RTS,S/AS01 malaria cases vs. non-malaria controls. These 35 BTMs  
505 were also examined as potential correlates of challenge outcome in each of the three CHMI studies.  
506 Significantly different expression is defined as FDR  $\leq 0.2$ , with adjustment across the 35 BTMs. All  
507 data shown are from participants who received the same vaccine regimen: a dose of RTS,S/AS01 at  
508 months 0, 1, and 2. MAL067, RNA-seq data from the MAL067 study in African infants and children;  
509 WRAIR 1032, Vahey et al. microarray data (43) from the WRAIR 1032 study in malaria-naïve adults  
510 (40); MAL068 RRR, RNA-seq data from the RRR arm in the MAL068 study in malaria-naïve adults  
511 (14); MAL071 RRR, RNA-seq data from the RRR arm in the MAL071 study in malaria-naïve adults  
512 (42). Cell color intensity represents the strength of the difference in the case vs. control comparison,  
513 expressed as signed  $\log_{10}$  false discovery rate (FDR); BTMs with significantly different expression  
514 (false discovery rate  $\leq 0.2$ ) between the two compared groups are outlined in black. Red, higher  
515 expression in RTS,S/AS01 cases vs. controls; blue, lower expression in RTS,S/AS01 cases vs. controls.  
516 High-level BTM annotation groups are shown in the left-most color bar.

517

518

519 We next performed the baseline correlates analysis of MAL067 (left-most column, Figure 6B).

520 Compared to the results from the month 3 analysis, the baseline correlates analysis of MAL067

521 revealed a larger number of BTMs whose month 0 levels (in vehicle-stimulated PBMC) associated

522 (nearly all positively) with clinical malaria risk (Figure 6B, Table S6B). These BTMs spanned many  
523 functional categories and were related to DCs, inflammation, and monocytes, among other areas. By far  
524 the strongest correlation with risk was with “enriched in monocytes (II) (M11.0)” (FDR = 4.74E-9),  
525 followed by “inflammatory response (M33)” (FDR = 1.48E-5) and “resting dendritic cell surface  
526 signature (S10)” (FDR = 2.69E-4). Comparing across studies, the greatest similarity seemed to be  
527 between MAL067 and WRAIR 1032, which shared 26 common BTMs associated with risk; of these,  
528 12 were also associated with risk in MAL068 RRR. Of note, the two functional annotations whose  
529 BTMs most consistently associated with risk across these three studies were “Dendritic cells” (“resting  
530 dendritic cell surface signature (S10)”, “complement and other receptors in DCs (M40)”, “DC surface  
531 signature (S5)”, and “enriched in dendritic cells (M168)” correlated with risk in all three studies) and  
532 “Monocytes” (“enriched in monocytes (I)”, “enriched in monocytes (II)”, “enriched in monocytes  
533 “IV”, and “monocyte surface signature (S4)” correlated with risk in all three studies).

534 In contrast to the multiple positive baseline transcriptional associations with risk in MAL067, WRAIR  
535 1032, and MAL068 RRR, nearly all the month 0 BTMs that associated with challenge outcome in  
536 MAL071 RRR were inversely associated with risk, including all the DC- and monocyte-related BTMs  
537 seen in the MAL067 signature. We did not find any obvious differences in study population or in  
538 sample collection/processing that could explain the differing results. It is also unknown why we see  
539 greater consistency in baseline transcriptional associations with risk across studies vs. month 3  
540 transcriptional associations with risk.

541 Baseline transcriptional associations with month 3 adaptive responses are presented in Figure S4 and  
542 Table S7. No significant associations were seen with any antibody responses. Among other functional  
543 BTM categories, baseline levels of three monocyte-related BTMs (“Monocyte surface signature (S4)”,  
544 “enriched in monocytes (II) (M11.0)”, and “enriched in myeloid cells and monocytes (M81)”), as well  
545 as two dendritic-cell-related BTMs (“resting dendritic cell surface signature (S10)” and “DC surface

546 signature (S5”)), all of which associated with risk in the above analysis, showed significant positive  
547 correlations with CSP-specific CD4+ T-cell polyfunctionality score.

548

549 *Monocyte frequencies tend to be higher at baseline and at month 3 in RTS,S/AS01 vaccinees that*  
550 *develop clinical malaria*

551 The finding that monocyte-related BTMs were expressed significantly higher in RTS,S/AS01 cases vs  
552 controls at month 3 in three of the four studies examined (Figure 6A) and at month 0 in three of the  
553 four studies examined (Figure 6B) suggested that monocyte frequencies may be higher in cases vs  
554 controls at these two timepoints. To determine if the monocyte-related transcriptional differences in  
555 PBMC were reflected in monocyte populations, the frequencies of monocytes in PBMC cases and  
556 controls were compared using immunophenotyping and flow cytometry. Figure S5A shows that, when  
557 automated gating (44) is performed, monocyte frequencies at month 0 and, to a lesser extent at month  
558 3, tend to be higher in cases than in controls for RTS,S/AS01 and comparator recipients combined.  
559 However, these differences were not significant (month 0  $p=0.131$ , month 3  $p=0.207$ ). When using  
560 manual gating, the inflammatory monocyte frequency and inflammatory monocyte/lymphocyte ratio  
561 (Figure S5B, S5C) also appeared to be higher in cases vs controls, at both month 3 and baseline, but  
562 again these differences were not significant. Thus, these findings do not support our hypothesis that the  
563 monocyte-related transcriptional differences in case vs. control PBMC would be reflected in these  
564 monocyte populations in cases vs. controls. A potential explanation for why we identified a baseline  
565 monocyte transcriptional signature of risk yet did not see an association of baseline monocyte  
566 frequency, inflammatory frequency, or inflammatory monocyte/lymphocyte ratio with risk, is that the  
567 baseline monocyte transcriptional signature of risk reflects expression changes in the existing  
568 circulating monocyte population, rather than an expansion in the circulating monocyte population.

569

## 570 **Discussion**

571 Our main finding is the identification of a baseline blood transcriptional module (BTM) signature,  
572 primarily related to dendritic cells, inflammation, and monocytes, that associates with clinical malaria  
573 risk in RTS,S/AS01-vaccinated African children. In a cross-study comparison, much of this baseline  
574 risk signature – specifically, dendritic cell- and monocyte-related BTMs – was also recapitulated in two  
575 of the three CHMI studies in healthy, malaria-naïve adults. Our finding fits into a growing body of  
576 evidence that baseline immune status can influence vaccine responses (45). Fourati et al. showed that  
577 higher baseline inflammation (as assessed by transcriptomic profiling and flow cytometric analysis of  
578 immune cell subset frequencies) was associated with poor antibody response to the hepatitis B vaccine  
579 (46). Tsang et al. showed that baseline interferon signaling was robustly correlated with maximum fold  
580 change (post-influenza vaccination to baseline) in influenza-specific antibody titer (47). The HIPC  
581 Consortium identified a baseline inflammatory gene signature that was associated with higher antibody  
582 responses to influenza vaccine in younger participants, yet lower antibody responses in older  
583 participants (48). Kotliarov et al. identified baseline transcriptional signatures that predicted antibody  
584 responses to the live attenuated yellow fever vaccine and to the trivalent inactivated influenza vaccine  
585 (49). Moreover, Hill et al. reported that increased baseline frequencies of plasmablasts and of  
586 circulating T follicular helper cells were associated with higher post-RTS,S/AS01 vaccination antibody  
587 titers (50). The mechanisms underlying the association found in the present study of baseline monocyte  
588 and inflammation-related gene expression with malaria risk in RTS,S/AS01 recipients are unknown,  
589 but this association does have potentially important implications, if this association is validated in  
590 additional studies of African children in malaria-endemic areas (as our cross-study comparison only  
591 looked at CHMI studies in malaria-naïve adults). For instance, an intriguing possibility is that  
592 prevaccination administration of anti-inflammatory drugs before vaccine inoculation may potentially  
593 reduce baseline inflammation and hence improve RTS,S/AS01-mediated protection. This strategy has  
594 been successfully followed in improving antibody responses to the 2012 seasonal influenza vaccine

595 (Arippal inactivated influenza vaccine) in the elderly (51), albeit it required a 6-week treatment course  
596 of the mTOR inhibitor RAD001. While such a treatment course would pose significant logistical  
597 challenges in our context, the general approach could potentially become more feasible if new (or  
598 existing) anti-inflammatory drugs are found that would require shorter administration periods; there is  
599 currently substantial interest towards taking such an approach to improve vaccine response e.g. in older  
600 adults (52).

601

602 The role of inflammatory monocytes in vaccine-immunity is an area of active research, however, the  
603 association of monocyte activity with clinical malaria risk is consistent with studies that have reported  
604 a positive correlation between monocyte to lymphocyte (ML) ratio and clinical malaria risk and/or  
605 severity (37, 38). Of note, the association between clinical malaria risk and ML ratio was found to be  
606 independent of both age and antibodies to parasite blood-stage antigens (38). Warimwe et al. reported  
607 that the ML ratio modifies the VE of RTS,S, where VE is lower at higher ML ratios (53). The results of  
608 Warimwe et al. raised the hypothesis that inflammatory monocytes may inhibit RTS,S-induced  
609 protective adaptive responses. Though the setting is different, the findings that monocytes inhibit T cell  
610 proliferation (54, 55), T cell activation (55), and B cell responses (56) in various mouse models of viral  
611 infection provide a potential basis for this hypothesis. Further studies are needed to determine whether  
612 such an inhibitory mechanism is at play in RTS,S vaccine immunity and whether strategies for  
613 modulating monocyte populations via chemokine receptor antagonists, as proposed by (55), could help  
614 boost RTS,S efficacy. However, here we found that baseline expression of monocyte-related BTMs  
615 was positively associated with post-vaccination CSP-specific polyfunctional CD4+ T cell responses. A  
616 potential explanation for this association may be more efficient antigen presentation to T cells upon  
617 vaccination in individuals with higher baseline expression of these monocyte-related BTMs. The  
618 association of month 3 levels of monocyte-related BTMs with risk may be independent from  
619 polyfunctional T cells, which we did not find to associate with risk or protection in this work.

620

621 Our finding of the association of monocyte signatures with malaria risk seem to contradict the results of  
622 a recent study in which we found that monocyte BTMs were associated with protection in RTS,S/AS01  
623 vaccinated children and infants (57). However, our previous monocyte-protection association was  
624 observed after analyzing gene expression levels in CSP-stimulated, background-corrected (i.e. after  
625 subtracting expression in vehicle-stimulated) PBMC (57), whereas the monocyte-risk association  
626 described in this study was observed after analyzing gene expression levels in vehicle-stimulated  
627 PBMC. Here, we did not detect BTMs associated with the response to RTS,S/AS01 vaccination or with  
628 protection when analyzing CSP-stimulated PBMC. This result is not surprising, given the low  
629 frequency of CSP-specific T-cells in RTS,S/AS01 vaccinees (e.g. on average, <0.10% of all CD4+ T  
630 cells (28)) and the number of T-cell non-responders based on the ICS data reported in this manuscript.  
631 In fact, in the previous study we could identify BTMs associated with RTS,S/AS01 vaccination in  
632 CSP-stimulated PBMC, but no differentially expressed genes were detected (57) and we had used  
633 different stimulation conditions and microarrays instead of RNAseq.

634

635 It is perhaps counterintuitive – considering that the RTS,S/AS01 vaccine does not contain AMA1 – that  
636 we observed a small number of BTMs associated with the response to RTS,S/AS01 vaccination and  
637 with clinical malaria risk when analyzing AMA1-stimulated PBMC. To explain this result, we refer the  
638 reader to our previous work that showed that RTS,S/AS01 vaccination alters antibody responses to  
639 antigens not contained in the RTS,S/AS01 vaccine (22). RTS,S/AS01 recipients received partial  
640 protection from the RTS,S/AS01 vaccine, leading possibly to decreased *P. falciparum* parasite load  
641 and/or exposure (infection). We hypothesize that the AMA1 stimulation activated T cells that had been  
642 previously primed by prior exposure to *P. falciparum* and that RTS,S/AS01 recipients had fewer  
643 primed T cells due to decreased *P. falciparum* infection (via partial RTS,S/AS01 protection), providing

644 a potential explanation for the transcriptional differences in AMA1-stimulated PBMC between  
645 RTS,S/AS01 vs comparator recipients.

646

647 We next discuss some limitations of our study. First, in malaria-naïve adults, the transcriptional  
648 response to the third RTS,S/AS01 dose has been shown to peak at Day 1 post-injection, with some  
649 decline by Day 6 and approximately 90% of the response having waned by Day 21 (16). Therefore, it is  
650 likely that the sampling scheme in this study (one month post-final dose) misses the majority of the  
651 transcriptional response to RTS,S/AS01. Future studies with dense, early post-vaccination PBMC  
652 sampling could be useful for further investigating RTS,S transcriptional immune correlates. Second,  
653 PBMCs were stimulated on site and then frozen. As each site performed the procedure separately, this  
654 renders our data susceptible to batch effects. However, a standardized SOP and shared reagents were  
655 used, decreasing the possibility of such effects. Moreover, an advantage of on-site stimulation of fresh  
656 PBMC is that it avoids the decrease in cell viability, and potential loss of detection of Ag-specific cells,  
657 that may have occurred if PBMC had been frozen, thawed, and then stimulated at a central location.  
658 Third, there was confounding between age and location. As all infants were from Manhiça and the  
659 majority of children were from Bagamoyo, it was not possible to examine the impact of age or clinical  
660 trial site on RTS,S/AS01 transcriptional response. Fourth, as only patrolling cell subsets are present in  
661 PBMC, we were unable to detect potential signals from T cells, B cells, NK cells, and macrophages  
662 localized to an infection site including skin and liver or the immune memory compartment localized in  
663 secondary lymphoid organs.

664

665 Despite these limitations, our study also has a number of strengths. For example, while excellent work  
666 has already been done to interrogate transcriptional responses to RTS,S/AS01 vaccination in healthy,  
667 malaria-naïve adults (including densely sampled early post-vaccination sampling timepoints to capture  
668 innate responses) and to identify molecular correlates of RTS,S/AS01-mediated protection against



669 clinical malaria after CHMI in malaria-naïve adults (16, 17, 43, 58), in our study we examined  
670 transcriptional responses to RTS,S/AS01 vaccination in infants and children in malaria-endemic areas.  
671 This feature is a strength of our study, as 1) infants in particular have relatively immature immune  
672 systems (59), making it likely that infants (and younger children) mount different vaccine responses  
673 than adults (60); 2) infants and children are especially susceptible to malaria-related morbidity and  
674 mortality, making them the target population for this and other malaria vaccines; and 3) continual  
675 exposure to *P. falciparum*, as occurs in endemic areas, influences naturally acquired immunity, which  
676 in turn interacts with immunity conferred by RTS,S vaccination (22). Related to this, another advantage  
677 of our study is the use of a comparator group which allows to discern the effect of the vaccine from  
678 environmental exposures including *P. falciparum* and age. As participants in the study are very young,  
679 significant development of their immune systems occurs throughout the duration of the study, meaning  
680 that such changes could potentially be confounded with vaccine-induced immune changes.

681

682 While it will be necessary to perform follow-up studies at more sites and with larger sample sizes to  
683 validate the baseline transcriptional signature associated with malaria risk identified here, our study  
684 raises interesting hypotheses related to the relationship of inflammation and RTS,S/AS01-mediated  
685 protection and suggests potential strategies to explore for augmenting RTS,S/AS01 VE.

686

## 687 **Acknowledgments**

688 We are very grateful to study participants, their families, and vaccine trial site field and lab staff. We  
689 thank the Phase 3 trial sites PIs Salim Abdulla, Pedro Alonso, Jahit Sacarlal, and Pedro Aide; the  
690 investigators involved in the generation of immunology data used here, including providers of antigens  
691 for antibody assays (Itziar Ubillos, Marta Vidal, Alfons Jimenez, Ruth Aguilar, Diana Barrios, Laura  
692 Puyol, Aintzane Ayestaran, Luis Izquierdo, David Cavanagh, James Beeson, David Lanar, Vir

693 Chauhan, Chetan Chitnis, Deepak Gaur, Evelina Angov, Benoit Gamain, Ross Coppel); the MAL067  
694 Vaccine Immunology Consortium investigators and Working Groups; and Fergal Duffy for valuable  
695 comments on the manuscript. We thank GlaxoSmithKline Biologicals S.A. for their support in the  
696 conduct of the MAL067 study.

697

## 698 **Conflicts of interest**

699 The authors have no conflicts of interest to declare.

700

## 701 **Funding**

702 Funding was obtained from the NIH-NIAID (R01AI095789), NIH-NIAID (U19AI128914), PATH  
703 Malaria Vaccine Initiative (MVI), Ministerio de Economía y Competitividad (Instituto de Salud Carlos  
704 III, PI11/00423 and PI14/01422). The RNA-seq project has been funded in whole or in part with  
705 Federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of  
706 Health, Department of Health and Human Services, under Grant Number U19AI110818 to the Broad  
707 Institute. This study was also supported by the Vaccine Statistical Support (Bill and Melinda Gates  
708 Foundation award INV-008576/OPP1154739 to R.G.). C.D. was the recipient of a Ramon y Cajal  
709 Contract from the Ministerio de Economía y Competitividad (RYC-2008-02631). G.M. was the  
710 recipient of a Sara Borrell–ISCIII fellowship (CD010/00156) and work was performed with the support  
711 of Department of Health, Catalan Government grant (SLT006/17/00109). This research is part of the  
712 ISGlobal’s Program on the Molecular Mechanisms of Malaria which is partially supported by the  
713 Fundación Ramón Areces and we acknowledge support from the Spanish Ministry of Science and  
714 Innovation through the “Centro de Excelencia Severo Ochoa 2019-2023” Program (CEX2018-000806-  
715 S), and support from the Generalitat de Catalunya through the CERCA Program.

716

717

## 718 **References**

719

720 1. World Health Organization. World Malaria Report 2020. Available at

721 <https://www.who.int/publications/i/item/9789240015791> 30 Nov 2020. Access date 24 Feb 2021. 2020.

722 2. Yang GG, Kim D, Pham A, Paul CJ. A Meta-Regression Analysis of the Effectiveness of

723 Mosquito Nets for Malaria Control: The Value of Long-Lasting Insecticide Nets. *Int J Environ Res*

724 *Public Health*. 2018;15(3).

725 3. Eisele TP. Mass drug administration can be a valuable addition to the malaria elimination

726 toolbox. *Malar J*. 2019;18(1):281.

727 4. Healer J, Cowman AF, Kaslow DC, Birkett AJ. Vaccines to Accelerate Malaria Elimination and

728 Eventual Eradication. *Cold Spring Harb Perspect Med*. 2017;7(9).

729 5. Beeson JG, Kurtovic L, Dobano C, Opi DH, Chan JA, Feng G, Good MF, Reiling L, Boyle MJ.

730 Challenges and strategies for developing efficacious and long-lasting malaria vaccines. *Sci Transl Med*.

731 2019;11(474).

732 6. Hoffman SL, Vekemans J, Richie TL, Duffy PE. The march toward malaria vaccines. *Vaccine*.

733 2015;33 Suppl 4:D13-23.

734 7. Gordon DM, McGovern TW, Krzych U, Cohen JC, Schneider I, LaChance R, Heppner DG,

735 Yuan G, Hollingdale M, Slaoui M, et al. Safety, immunogenicity, and efficacy of a recombinantly

736 produced *Plasmodium falciparum* circumsporozoite protein-hepatitis B surface antigen subunit vaccine.

737 *J Infect Dis*. 1995;171(6):1576-85.

738 8. RTS, S Clinical Trials Partnership. First results of phase 3 trial of RTS,S/AS01 malaria vaccine

739 in African children. *N Engl J Med*. 2011;365(20):1863-75.

740 9. RTS, S Clinical Trials Partnership. A phase 3 trial of RTS, S/AS01 malaria vaccine in African

741 infants. *New England Journal of Medicine*. 2012;367(24):2284-95.

- 742 10. RTS, S Clinical Trials Partnership. Efficacy and safety of the RTS,S/AS01 malaria vaccine  
743 during 18 months after vaccination: a phase 3 randomized, controlled trial in children and young  
744 infants at 11 African sites. *PLoS Med.* 2014;11(7):e1001685.
- 745 11. RTS, S Clinical Trials Partnership. Efficacy and safety of RTS,S/AS01 malaria vaccine with or  
746 without a booster dose in infants and children in Africa: final results of a phase 3, individually  
747 randomised, controlled trial. *Lancet.* 2015;386(9988):31-45.
- 748 12. Hawkes N. European Medicines Agency approves first malaria vaccine. *BMJ.* 2015;351:h4067.
- 749 13. World Health Organization. Q&A on the malaria vaccine implementation programme (MVIP).  
750 November 2019. <https://www.who.int/malaria/media/malaria-vaccine-implementation-qa/en/> Access  
751 date Nov 29, 2019.
- 752 14. Ockenhouse CF, Regules J, Tosh D, Cowden J, Kathcart A, Cummings J, Paolino K, Moon J,  
753 Komisar J, Kamau E, Oliver T, Chhoeu A, Murphy J, Lyke K, Laurens M, Birkett A, Lee C, Weltzin  
754 R, Wille-Reece U, Sedegah M, Hendriks J, Versteeg I, Pau MG, Sadoff J, Vanloubbeeck Y, Lievens  
755 M, Heerwegh D, Moris P, Guerra Mendoza Y, Jongert E, Cohen J, Voss G, Ballou WR, Vekemans J.  
756 Ad35.CS.01-RTS,S/AS01 Heterologous Prime Boost Vaccine Efficacy against Sporozoite Challenge in  
757 Healthy Malaria-Naive Adults. *PLoS One.* 2015;10(7):e0131571.
- 758 15. Chaudhury S, Ockenhouse CF, Regules JA, Dutta S, Wallqvist A, Jongert E, Waters NC,  
759 Lemiale F, Bergmann-Leitner E. The biological function of antibodies induced by the RTS,S/AS01  
760 malaria vaccine candidate is determined by their fine specificity. *Malar J.* 2016;15:301.
- 761 16. Kazmin D, Nakaya HI, Lee EK, Johnson MJ, van der Most R, van den Berg RA, Ballou WR,  
762 Jongert E, Wille-Reece U, Ockenhouse C, Aderem A, Zak DE, Sadoff J, Hendriks J, Wrammert J,  
763 Ahmed R, Pulendran B. Systems analysis of protective immune responses to RTS,S malaria  
764 vaccination in humans. *Proc Natl Acad Sci U S A.* 2017;114(9):2425-30.
- 765 17. Du Y, Thompson EG, Muller J, Valvo J, Braun J, Shankar S, van den Berg RA, Jongert E,  
766 Dover D, Sadoff J, Hendriks J, Gardner MJ, Ballou WR, Regules JA, van der Most R, Aderem A,

- 767 Ockenhouse CF, Hill AV, Wille-Reece U, Zak DE. The Ratiometric Transcript Signature  
768 MX2/GPR183 Is Consistently Associated With RTS,S-Mediated Protection Against Controlled Human  
769 Malaria Infection. *Frontiers in Immunology*. 2020;11(669).
- 770 18. Pallikkuth S, Chaudhury S, Lu P, Pan L, Jongert E, Wille-Reece U, Pahwa S. A delayed  
771 fractionated dose RTS,S AS01 vaccine regimen mediates protection via improved T follicular helper  
772 and B cell responses. *Elife*. 2020;9.
- 773 19. Suscovich TJ, Fallon JK, Das J, Demas AR, Crain J, Linde CH, Michell A, Natarajan H,  
774 Arevalo C, Broge T, Linnekin T, Kulkarni V, Lu R, Slein MD, Luedemann C, Marquette M, March S,  
775 Weiner J, Gregory S, Coccia M, Flores-Garcia Y, Zavala F, Ackerman ME, Bergmann-Leitner E,  
776 Hendriks J, Sadoff J, Dutta S, Bhatia SN, Lauffenburger DA, Jongert E, Wille-Reece U, Alter G.  
777 Mapping functional humoral correlates of protection against malaria challenge following RTS,S/AS01  
778 vaccination. *Sci Transl Med*. 2020;12(553).
- 779 20. Dennison SM, Reichartz M, Abraha M, Spreng RL, Wille-Reece U, Dutta S, Jongert E, Alam  
780 SM, Tomaras GD. Magnitude, specificity and avidity of sporozoite specific antibodies associate with  
781 protection status and distinguish among RTS,S/AS01 dose regimens. *Open Forum Infectious Diseases*.  
782 2020.
- 783 21. Dobano C, Sanz H, Sorgho H, Dosoo D, Mpina M, Ubillos I, Aguilar R, Ford T, Diez-Padrisa  
784 N, Williams NA, Ayestaran A, Traore O, Nhabomba AJ, Jairoce C, Waitumbi J, Agnandji ST, Kariuki  
785 S, Abdulla S, Aponte JJ, Mordmuller B, Asante KP, Owusu-Agyei S, Tinto H, Campo JJ, Moncunill G,  
786 Gyan B, Valim C, Daubenberger C. Concentration and avidity of antibodies to different  
787 circumsporozoite epitopes correlate with RTS,S/AS01E malaria vaccine efficacy. *Nat Commun*.  
788 2019;10(1):2174.
- 789 22. Dobano C, Ubillos I, Jairoce C, Gyan B, Vidal M, Jimenez A, Santano R, Dosoo D, Nhabomba  
790 AJ, Ayestaran A, Aguilar R, Williams NA, Diez-Padrisa N, Lanar D, Chauhan V, Chitnis C, Dutta S,  
791 Gaur D, Angov E, Asante KP, Owusu-Agyei S, Valim C, Gamain B, Coppel RL, Cavanagh D, Beeson

- 792 JG, Campo JJ, Moncunill G. RTS,S/AS01E immunization increases antibody responses to vaccine-  
793 unrelated Plasmodium falciparum antigens associated with protection against clinical malaria in  
794 African children: a case-control study. *BMC Med.* 2019;17(1):157.
- 795 23. Ubillos I, Ayestaran A, Nhabomba AJ, Dosoo D, Vidal M, Jimenez A, Jairoce C, Sanz H,  
796 Aguilar R, Williams NA, Diez-Padrisa N, Mpina M, Sorgho H, Agnandji ST, Kariuki S, Mordmuller  
797 B, Daubenberger C, Asante KP, Owusu-Agyei S, Sacarlal J, Aide P, Aponte JJ, Dutta S, Gyan B,  
798 Campo JJ, Valim C, Moncunill G, Dobano C. Baseline exposure, antibody subclass, and hepatitis B  
799 response differentially affect malaria protective immunity following RTS,S/AS01E vaccination in  
800 African children. *BMC Med.* 2018;16(1):197.
- 801 24. Moncunill G, Mpina M, Nhabomba AJ, Aguilar R, Ayestaran A, Sanz H, Campo JJ, Jairoce C,  
802 Barrios D, Dong Y, Diez-Padrisa N, Fernandes JF, Abdulla S, Sacarlal J, Williams NA, Harezlak J,  
803 Mordmuller B, Agnandji ST, Aponte JJ, Daubenberger C, Valim C, Dobano C. Distinct Helper T Cell  
804 Type 1 and 2 Responses Associated With Malaria Protection and Risk in RTS,S/AS01E Vaccinees.  
805 *Clin Infect Dis.* 2017;65(5):746-55.
- 806 25. Moris P, Jongert E, van der Most RG. Characterization of T-cell immune responses in clinical  
807 trials of the candidate RTS,S malaria vaccine. *Hum Vaccin Immunother.* 2018;14(1):17-27.
- 808 26. Moncunill G, Han H, Dobano C, McElrath MJ, De Rosa SC. OMIP-024: pan-leukocyte  
809 immunophenotypic characterization of PBMC subsets in human samples. *Cytometry A.*  
810 2014;85(12):995-8.
- 811 27. Moncunill G, Dobano C, McElrath MJ, De Rosa SC. OMIP-025: evaluation of human T- and  
812 NK-cell responses including memory and follicular helper phenotype by intracellular cytokine staining.  
813 *Cytometry A.* 2015;87(4):289-92.
- 814 28. Moncunill G, De Rosa SC, Ayestaran A, Nhabomba AJ, Mpina M, Cohen KW, Jairoce C,  
815 Rutishauser T, Campo JJ, Harezlak J, Sanz H, Diez-Padrisa N, Williams NA, Morris D, Aponte JJ,  
816 Valim C, Daubenberger C, Dobano C, McElrath MJ. RTS,S/AS01E Malaria Vaccine Induces Memory

- 817 and Polyfunctional T Cell Responses in a Pediatric African Phase III Trial. *Front Immunol.*  
818 2017;8:1008.
- 819 29. Robinson MD, Oshlack A. A scaling normalization method for differential expression analysis  
820 of RNA-seq data. *Genome Biol.* 2010;11(3):R25.
- 821 30. Law CW, Chen Y, Shi W, Smyth GK. voom: Precision weights unlock linear model analysis  
822 tools for RNA-seq read counts. *Genome Biol.* 2014;15(2):R29.
- 823 31. Smyth GK. Linear models and empirical bayes methods for assessing differential expression in  
824 microarray experiments. *Stat Appl Genet Mol Biol.* 2004;3:Article3.
- 825 32. Wu D, Smyth GK. Camera: a competitive gene set test accounting for inter-gene correlation.  
826 *Nucleic Acids Res.* 2012;40(17):e133.
- 827 33. Benjamini Y, Hochberg Y. Controlling the False Discovery Rate - a Practical and Powerful  
828 Approach to Multiple Testing. *J R Stat Soc B.* 1995;57(1):289-300.
- 829 34. Li S, Roupheal N, Duraisingham S, Romero-Steiner S, Presnell S, Davis C, Schmidt DS,  
830 Johnson SE, Milton A, Rajam G, Kasturi S, Carlone GM, Quinn C, Chaussabel D, Palucka AK,  
831 Mulligan MJ, Ahmed R, Stephens DS, Nakaya HI, Pulendran B. Molecular signatures of antibody  
832 responses derived from a systems biology study of five human vaccines. *Nature Immunology.*  
833 2014;15(2):195-204.
- 834 35. Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, Smyth GK. limma powers differential  
835 expression analyses for RNA-sequencing and microarray studies. *Nucleic Acids Res.* 2015;43(7):e47.
- 836 36. Bueno LL, Fujiwara RT, Soares IS, Braga EM. Direct effect of Plasmodium vivax recombinant  
837 vaccine candidates AMA-1 and MSP-119 on the innate immune response. *Vaccine.* 2008;26(9):1204-  
838 13.
- 839 37. Antwi-Baffour S, Kyeremeh R, Buabeng D, Adjei JK, Aryeh C, Kpentey G, Seidu MA.  
840 Correlation of malaria parasitaemia with peripheral blood monocyte to lymphocyte ratio as indicator of  
841 susceptibility to severe malaria in Ghanaian children. *Malar J.* 2018;17(1):419.

- 842 38. Warimwe GM, Murungi LM, Kamuyu G, Nyangweso GM, Wambua J, Naranbhai V, Fletcher  
843 HA, Hill AV, Bejon P, Osier FH, Marsh K. The ratio of monocytes to lymphocytes in peripheral blood  
844 correlates with increased susceptibility to clinical malaria in Kenyan children. *PLoS One*.  
845 2013;8(2):e57320.
- 846 39. Lin L, Finak G, Ushey K, Seshadri C, Hawn TR, Frahm N, Scriba TJ, Mahomed H, Hanekom  
847 W, Bart PA, Pantaleo G, Tomaras GD, Rerks-Ngarm S, Kaewkungwal J, Nitayaphan S, Pitisuttithum  
848 P, Michael NL, Kim JH, Robb ML, O'Connell RJ, Karasavvas N, Gilbert P, S CDR, McElrath MJ,  
849 Gottardo R. COMPASS identifies T-cell subsets correlated with clinical outcomes. *Nat Biotechnol*.  
850 2015;33(6):610-6.
- 851 40. Kester KE, Cummings JF, Ofori-Anyinam O, Ockenhouse CF, Krzych U, Moris P, Schwenk R,  
852 Nielsen RA, Debebe Z, Pinelis E, Juompan L, Williams J, Dowler M, Stewart VA, Wirtz RA, Dubois  
853 MC, Lievens M, Cohen J, Ballou WR, Heppner DG, Jr., Rts SVEG. Randomized, double-blind, phase  
854 2a trial of falciparum malaria vaccines RTS,S/AS01B and RTS,S/AS02A in malaria-naive adults:  
855 safety, efficacy, and immunologic associates of protection. *J Infect Dis*. 2009;200(3):337-46.
- 856 41. Sun P, Schwenk R, White K, Stoute JA, Cohen J, Ballou WR, Voss G, Kester KE, Heppner  
857 DG, Krzych U. Protective immunity induced with malaria vaccine, RTS,S, is linked to *Plasmodium*  
858 falciparum circumsporozoite protein-specific CD4<sup>+</sup> and CD8<sup>+</sup> T cells producing IFN-gamma. *J*  
859 *Immunol*. 2003;171(12):6961-7.
- 860 42. Regules JA, Cicatelli SB, Bennett JW, Paolino KM, Twomey PS, Moon JE, Kathcart AK,  
861 Hauns KD, Komisar JL, Qabar AN, Davidson SA, Dutta S, Griffith ME, Magee CD, Wojnarski M,  
862 Livezey JR, Kress AT, Waterman PE, Jongert E, Wille-Reece U, Volkmuth W, Emerling D, Robinson  
863 WH, Lievens M, Morelle D, Lee CK, Yassin-Rajkumar B, Weltzin R, Cohen J, Paris RM, Waters NC,  
864 Birkett AJ, Kaslow DC, Ballou WR, Ockenhouse CF, Vekemans J. Fractional Third and Fourth Dose  
865 of RTS,S/AS01 Malaria Candidate Vaccine: A Phase 2a Controlled Human Malaria Parasite Infection  
866 and Immunogenicity Study. *J Infect Dis*. 2016;214(5):762-71.



- 867 43. Vahey MT, Wang Z, Kester KE, Cummings J, Heppner DG, Jr., Nau ME, Ofori-Anyinam O,  
868 Cohen J, Coche T, Ballou WR, Ockenhouse CF. Expression of genes associated with  
869 immunoproteasome processing of major histocompatibility complex peptides is indicative of protection  
870 with adjuvanted RTS,S malaria vaccine. *J Infect Dis.* 2010;201(4):580-9.
- 871 44. Greene E, Finak G, D'Amico LA, Bhardwaj N, Church CD, Morishima C, Ramchurren N,  
872 Taube JM, Nghiem PT, Cheever MA, Fling SP, Gottardo R. A new data-driven cell population  
873 discovery and annotation method for single-cell data, FAUST, reveals correlates of clinical response to  
874 cancer immunotherapy. *bioRxiv.* 2019:702118.
- 875 45. Tsang JS, Dobano C, VanDamme P, Moncunill G, Marchant A, Othman RB, Sadarangani M,  
876 Koff WC, Kollmann TR. Improving Vaccine-Induced Immunity: Can Baseline Predict Outcome?  
877 *Trends Immunol.* 2020;41(6):457-65.
- 878 46. Fourati S, Cristescu R, Loboda A, Talla A, Filali A, Railkar R, Schaeffer AK, Favre D, Gagnon  
879 D, Peretz Y, Wang IM, Beals CR, Casimiro DR, Carayannopoulos LN, Sekaly RP. Pre-vaccination  
880 inflammation and B-cell signalling predict age-related hyporesponse to hepatitis B vaccination. *Nat*  
881 *Commun.* 2016;7:10369.
- 882 47. Tsang JS, Schwartzberg PL, Kotliarov Y, Biancotto A, Xie Z, Germain RN, Wang E, Olnes MJ,  
883 Narayanan M, Golding H, Moir S, Dickler HB, Perl S, Cheung F, Baylor HC, Consortium CHI. Global  
884 analyses of human immune variation reveal baseline predictors of postvaccination responses. *Cell.*  
885 2014;157(2):499-513.
- 886 48. HIPC-CHI Signatures Project Team, HIPC-I Consortium. Multicohort analysis reveals baseline  
887 transcriptional predictors of influenza vaccination responses. *Sci Immunol.* 2017;2(14).
- 888 49. Kotliarov Y, Sparks R, Martins AJ, Mule MP, Lu Y, Goswami M, Kardava L, Banchereau R,  
889 Pascual V, Biancotto A, Chen J, Schwartzberg PL, Bansal N, Liu CC, Cheung F, Moir S, Tsang JS.  
890 Broad immune activation underlies shared set point signatures for vaccine responsiveness in healthy  
891 individuals and disease activity in patients with lupus. *Nat Med.* 2020;26(4):618-29.

- 892 50. Hill DL, Carr EJ, Rutishauser T, Moncunill G, Campo JJ, Innocentin S, Mpina M, Nhabomba  
893 A, Tumbo A, Jairoce C, Moll HA, van Zelm MC, Dobano C, Daubenberger C, Linterman MA.  
894 Immune system development varies according to age, location, and anemia in African children. *Sci*  
895 *Transl Med.* 2020;12(529).
- 896 51. Mannick JB, Del Giudice G, Lattanzi M, Valiante NM, Praestgaard J, Huang B, Lonetto MA,  
897 Maecker HT, Kovarik J, Carson S, Glass DJ, Klickstein LB. mTOR inhibition improves immune  
898 function in the elderly. *Sci Transl Med.* 2014;6(268):268ra179.
- 899 52. Pereira B, Xu XN, Akbar AN. Targeting Inflammation and Immunosenescence to Improve  
900 Vaccine Responses in the Elderly. *Front Immunol.* 2020;11:583019.
- 901 53. Warimwe GM, Fletcher HA, Olotu A, Agnandji ST, Hill AV, Marsh K, Bejon P. Peripheral  
902 blood monocyte-to-lymphocyte ratio at study enrollment predicts efficacy of the RTS,S malaria  
903 vaccine: analysis of pooled phase II clinical trial data. *BMC Med.* 2013;11:184.
- 904 54. Norris BA, Uebelhoer LS, Nakaya HI, Price AA, Grakoui A, Pulendran B. Chronic but not  
905 acute virus infection induces sustained expansion of myeloid suppressor cell numbers that inhibit viral-  
906 specific T cell immunity. *Immunity.* 2013;38(2):309-21.
- 907 55. Mitchell LA, Henderson AJ, Dow SW. Suppression of vaccine immunity by inflammatory  
908 monocytes. *J Immunol.* 2012;189(12):5612-21.
- 909 56. Sannicelli S, Kuka M, Di Lucia P, de Oya NJ, De Giovanni M, Fioravanti J, Cristofani C,  
910 Maganuco CG, Fallet B, Ganzer L, Sironi L, Mainetti M, Ostuni R, Larimore K, Greenberg PD, de la  
911 Torre JC, Guidotti LG, Iannacone M. Inflammatory monocytes hinder antiviral B cell responses. *Sci*  
912 *Immunol.* 2016;1(4).
- 913 57. Moncunill G, Scholzen A, Mpina M, Nhabomba A, Hounkpatin AB, Osaba L, Valls R, Campo  
914 JJ, Sanz H, Jairoce C, Williams NA, Pasini EM, Arteta D, Maynou J, Palacios L, Duran-Frigola M,  
915 Aponte JJ, Kocken CHM, Agnandji ST, Mas JM, Mordmuller B, Daubenberger C, Sauerwein R,

- 916 Dobano C. Antigen-stimulated PBMC transcriptional protective signatures for malaria immunization.  
917 Sci Transl Med. 2020;12(543).
- 918 58. van den Berg RA, Coccia M, Ballou WR, Kester KE, Ockenhouse CF, Vekemans J, Jongert E,  
919 Didierlaurent AM, van der Most RG. Predicting RTS,S Vaccine-Mediated Protection from  
920 Transcriptomes in a Malaria-Challenge Clinical Trial. Front Immunol. 2017;8:557.
- 921 59. Simon AK, Hollander GA, McMichael A. Evolution of the immune system in humans from  
922 infancy to old age. Proc Biol Sci. 2015;282(1821):20143085.
- 923 60. Pichichero ME. Challenges in vaccination of neonates, infants and young children. Vaccine.  
924 2014;32(31):3886-94.
- 925

926  
927

## Supplementary Material

928  
929

### 930 **Supplementary Methods**

931

932 Quality control of RNA sequencing data: Multidimensional scaling (MDS) plots as implemented in the

933 plotMDS function of the limma package were used to visualize variability across samples and identify

934 potential abnormalities (batch effects, outliers) or patterns of biological interest (association within

935 experimental factors).


936

937

938


939 **Figure S1. Associations of month 3 levels of RTS,S/AS01 signature blood transcriptional modules**  
 940 **(BTMs) with malaria case status in comparator recipients.** Heatmap showing which of the 59  
 941 down-selected RTS,S/AS01 signature BTMs (Comparison 1) showed significantly different expression  
 942 [false discovery rate (FDR)  $\leq 0.2$ ] in month 3 PBMC between comparator cases vs. non-malaria  
 943 controls in DMSO-stimulated PBMC. Analyses were also done with Ag-stimulated PBMC but are not  
 944 shown here as none of the results were significant (only DMSO had any significant BTMs). Cell color  
 945 intensity represents the strength of the difference in the relevant comparison, expressed as signed log<sub>10</sub>  
 946 FDR. Red, higher expression in comparator cases vs. controls; blue, lower expression in comparator  
 947 cases vs. controls. High-level BTM annotation groups are shown in the left-most color bar.

948




949

950 **Figure S2: A) Polyfunctionality score and B) magnitude of CSP-specific CD4+ T-cell responses in**  
951 **RTS,S/AS01 vaccine recipients at month 3, stratified by case (clinical malaria)-control status.**




952  
953  
954

955 **Figure S3: Correlations of transcriptional and adaptive responses in comparator vaccine**  
 956 **recipients.** Heatmap showing significant correlations between month 3 levels of RTS,S/AS01  
 957 signature BTMs and month 3 antibody and cellular responses in comparator recipients. Cell color  
 958 intensity represents the strength of the correlation; BTM/response pairs with significant correlations  
 959 [false discovery rate (FDR)  $\leq 0.2$ ] are outlined in black. Cell color represents correlation direction: red,  
 960 positive correlation; blue, negative correlation. High-level BTM annotation groups are shown in the  
 961 left-most color bar. The bottom bar denotes the type of adaptive response analyzed (orange, antibody;  
 962 purple, cellular). Green bar, IAVI measurements. 963



964  
965


966 **Figure S4. Correlations of Month 0 blood transcriptional module (BTM) expression with month**  
 967 **3 adaptive responses in RTS,S/AS01 vaccine recipients.** Heatmap showing significant correlations  
 968 between month 0 levels of RTS,S/AS01 signature BTMs and month 3 cellular responses (no significant  
 969 correlations were seen with any month 3 antibody responses). Cell color intensity represents the  
 970 strength of the correlation; BTM/response pairs with significant correlations [false discovery rate  
 971 (FDR)  $\leq 0.2$ ] are outlined in black. Cell color represents correlation direction: red, positive correlation;  
 972 blue, negative correlation. High-level BTM annotation groups are shown in the left-most color bar.



973



974 **Figure S5. RTS,S/AS01 cases tend to have higher monocyte frequencies than controls, at both**  
975 **baseline and at month 3.** (A) Monocyte frequencies in PBMC, (B) inflammatory monocyte counts in  
976 PBMC, and (C) ratios of inflammatory monocytes to lymphocytes. Data are shown separately in cases  
977 and in controls (RTS,S/AS01 recipients only) in each panel. (A) was assessed using FAUST; (B) and  
978 (C) were assessed using De Rosa flow immunophenotyping. “Inflammatory monocytes” refers to  
979 “HLA-DR+ CD14+CD16++” cells.



980  
981  
982  
983

984 **Table S1. Antibody reagents included in the ICS panel.**

985

<b>Specificity</b>	<b>Fluorochrome</b>	<b>Manufacturer</b>	<b>Catalog Number</b>
Live/dead	AVID*	Molecular Probes/Invitrogen	L34957
CD14	BV510*	BioLegend	301842
CD56	BUV737	BD Biosciences	564447
CD3	BV570	BioLegend	300436
CD4	BUV395	BD Biosciences	563550
CD8	BV650	BD Biosciences	563821
CD45RA	APC-H7	BD Biosciences	560674
CCR7	BV786	BioLegend	353229
CXCR5	PE-Dazzle594	BioLegend	356928
PD-1	PE-Cy7	eBioscience	25-2799-42
IFN- $\gamma$	V450	Becton Dickinson	560371
IL-2	PE	BD Biosciences	559334
IL-4	PerCP-Cy5.5	BioLegend	500822
IL-13	BV711	BD Biosciences	564288
IL-21	APC	Miltenyi Biotec	130-096-882
TNF- $\alpha$	FITC	eBioscience	11-7349-82
CD40L	BV605	BioLegend	310825
Granzyme B	Alx700	BD Biosciences	560213
*AVID and CD14 are detected in the same channel.			

986

987 **Table S2. Numbers, age group, and case-control status of RTS,S/AS01 recipients by site for**  
 988 **whom month 0 and/or month 3 PBMC samples were included in the ICS/immunophenotyping**  
 989 **analysis.**  
 990

<b>Month 0</b>				
<b>Overall Total (Totals for Bagomoyo, Manhiça, Lambaréné)</b>				
	<b>Cases</b>		<b>Controls</b>	
<b>Total</b>	<b>Infants</b>	<b>Children</b>	<b>Infants</b>	<b>Children</b>
110 (96, 4, 10)	0 (0, 0, 0)	24 (20, 1, 3)	0 (0, 0, 0)	86 (76, 3, 7)
<b>Month 3</b>				
<b>Overall Total (Totals for Bagomoyo, Manhiça, Lambaréné)</b>				
	<b>Cases</b>		<b>Controls</b>	
<b>Total</b>	<b>Infants</b>	<b>Children</b>	<b>Infants</b>	<b>Children</b>
304 (99, 131, 74)	35 (0, 25, 10)	31 (21, 1, 9)	133 (0, 102, 31)	105 (78, 3, 24)

991  
 992

993 (Tables S3 through S9 are uploaded as separate Excel files)

994

995 **Supplementary Table Legends, Tables S3 through S9**

996

997 Table S3. List of BTMs, p values, and FDRs for Comparison 1) RTS,S/AS01 vs comparator recipients

998 at month 3 and Comparison 2) RTS,S/AS01 recipients at month 3 vs month 0.

999 Table S4. List of all BTMs tested for significantly different expression in RTS,S/AS01 cases vs

1000 controls at month 3, along with stimulation, p value, and FDR results for each Comparison.

1001 Table S5. List of BTMs whose month 3 levels correlated significantly with at least one month 3

1002 adaptive response variable in RTS,S/AS01 vaccinees, along with stimulation, variable details, p value,

1003 and FDR results.

1004 Table S6. List of BTMs whose month 3 or month 0 levels had significantly different expression in

1005 RTS,S/AS01 cases vs. controls in MAL067, along with p values and FDR results when testing the

1006 MAL067 sets of correlate BTMs for significantly different expression in cases vs. controls in the

1007 WRAIR 1032, MAL068 RRR, and MAL071 RRR studies.

1008 Table S7. List of BTMs whose month 0 levels correlated significantly with at least one month 3

1009 adaptive response variable, along with stimulation, variable details, p value, and FDR results.

1010 Table S8. List of all BTMs with significantly different expression in comparator cases vs controls at

1011 month 3, along with p value and FDR results for each Comparison. Only vehicle had any significant

1012 (FDR  $\leq$  0.2) BTMs.

1013 Table S9. List of BTMs whose month 3 levels correlated significantly with at least one month 3

1014 adaptive response variable in comparator recipients, along with stimulation, variable details, p value,

1015 and FDR results.

1016